Novinky v biomedicínském výzkumu

přednáškové odpoledne s předními světovými odborníky

úterý 5. dubna 2016

Velká zasedací místnost děkanátu 1. LF UK (Na Bojišti 3, Praha 2)

1. LÉKAŘSKÁ FAKULTA Univerzita Karlova

Christoph Wanner

Is professor of medicine and chief of the Division of Nephrology Department of Medicine University Hospital of Würzburg Julius-Maximilians-University and Scientific director of Clinical Trial Unit, Würzburg, Germany. His research focusses on patients with chronic kidney disease. Particularly on the role of lipids in the progression of renal and vascular diseases (glomerulosclerosis and atherosclerosis) in kidney failure patients and on the elucidation of the inflammatory response syndrome in diabetic nephropathy, chronic kidney disease, and kidney failure. He served as principal investigator of Deutsche Diabetes Dialyse Studie (4D) study and steering committee member and central Europe coordinator of Heart and Renal Protection study (SHARP), among others. Those clinical studies tested the efficacy of statins in diabetic patients on dialysis and chronic kidney disease patients, respectively.

13.45 Registration for students

14.00 Cardiovascular biomarkers in patients with normal and impaired kidney function

Cardiac biomarkers in conjunction with symptoms, electrocardiographic (ECG) changes, and cardiac imaging are used to diagnose acute myocardial infarction (AMI) and to predict short- and long-term adverse outcomes. In patients with impaired kidney function the cardiac biomarkers are often elevated. The relative contribution of cardiovascular condition and delayed clearance of cardiovascular biomarkers in patients with impaired kidney functions will be discussed.

14.40 New options of hypolipidemic treatment

Hyperlipidemia is a condition in which lipid and/or lipoprotein levels in the blood are elevated. It can significantly increase the risk of cardiovascular disease. Hyperlipidemia is, beside genetic factors, often caused or exacerbated by uncontrolled diabetes mellitus, obesity, medication, and life style habits. In addition to statins, 3 classes of medications are currently used for the management of major lipid elevations: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, fibric acid derivatives and omega-3 fatty acids. The presentation will also focus on new hypolipidemic drugs in preclinical and clinical phase of development, such as cholesterylester transfer protein (CETP) inhibitors and squalene synthase inhibitors, and therapy consideration in patients in high risk groups.

15.20 Registries, cohort studies and randomized controlled trials for different questions

The quality of finding obtained from research study depends on how the study was designed (hierarchy of study designs). The presentation will focus on the research questions appropriate for registries, cohort studies, and controlled trials. The specific clinical questions of interest will guide the study design, data collection, analysis, definitions of study subjects, and outcome measures.

16.00 – 16.20 Information (20 minutes) on how to prepare for the defence of the doctoral thesis (an example from Wuerzburg and/or other German Universities).

Přednáškové odpoledne **je součástí kurzu „Novinky v biomedicínském výzkumu**“, který je jeden z doporučených povinně volitelných kurzů **pro Ph.D. studenty oboru Biochemie a patobiochemie (Oborová rada 04**) a **Fyziologie a patofyziologie člověka (Oborová rada 05).** Účastníci na konci kurzu získají zápočet. Kurz je sestaven z přednášek zahraničních a domácích světově uznávaných odborníků zabývajících se molekulovými mechanismy etiologie, patogeneze a terapie chorob. Vítáni jsou i studenti jiných oborů a zájemci z řad vědeckých pracovníků a lékařů.

Contact information:
Doc. MUDr. Jan Živný, Ph.D., **jzivny@lf1.cuni.cz**, tel: 22496-5865
Prof. MUDr. Stanislav Šípek, DrSc., **stipekst@lf1.cuni.cz**, tel: 22496-4283